Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-08-09

Clinical Trial Update: A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD [Phase 4]

View source ↗

Summary

Phase 4 trial update reporting efficacy and safety of NVA237 in moderate to severe COPD, completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NVA237

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease | Phase 4 | Status: COMPLETED | Results posted: 2019-08-09